Expanding upon our previous studies with our lead Mnk1/2 protein degrader VNLG-152R, in a variety of breast cancer subtypes, in vitro [39], we focused on studying the impact of VNLG-152R and its two pure enantiomers, specifically in several in vitro human triple negative breast cancer (TNBC) subtypes and in vivo xenograft and metastasis models of TNBC. The gene discussed is MKNK1; the disease is triple-negative breast carcinoma.